Education
About Us
Working with TipRanks
Follow Us
ZyVersa Therapeutics (ZVSA)
OTHER OTC:ZVSA
ZVSA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.12 - $4.20
Previous CloseN/A
Volume38.43K
Average Volume (3M)8.47M
Market Cap
$1.17M
Enterprise Value$8.45M
Total Cash (Recent Filing)$1.61B
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.59
Next Earnings
Aug 25, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.73
Shares Outstanding7,935,921
10 Day Avg. Volume2,380,527
30 Day Avg. Volume8,472,886
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.14
Price to Sales (P/S)0.00
P/FCF Ratio-9.53
Enterprise Value/Market Cap7.22
Enterprise Value/Revenue270.86
Enterprise Value/Gross Profit809.53
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$20.00Price Target Upside13233.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
ZyVersa Therapeutics News
PremiumCompany Announcements
ZyVersa Therapeutics Faces Nasdaq Delisting, Plans Pink Market Move
PremiumCompany Announcements
ZyVersa Therapeutics Enters Warrant Exercise AgreementOptions Prices
Currently, No data available
---
Ownership Overview
11.03%
Insiders
0.16% Mutual Funds
0.36% Other Institutional Investors
88.45% Public Companies and
Individual Investors
ZVSA FAQ
What was ZyVersa Therapeutics’s price range in the past 12 months?
ZyVersa Therapeutics lowest stock price was $0.12 and its highest was $4.20 in the past 12 months.
What is ZyVersa Therapeutics’s market cap?
ZyVersa Therapeutics’s market cap is $1.17M.
When is ZyVersa Therapeutics’s upcoming earnings report date?
ZyVersa Therapeutics’s upcoming earnings report date is Aug 25, 2025 which is in 32 days.
How were ZyVersa Therapeutics’s earnings last quarter?
Currently, no data Available
Is ZyVersa Therapeutics overvalued?
According to Wall Street analysts ZyVersa Therapeutics’s price is currently Undervalued.
Does ZyVersa Therapeutics pay dividends?
ZyVersa Therapeutics does not currently pay dividends.
What is ZyVersa Therapeutics’s EPS estimate?
ZyVersa Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ZyVersa Therapeutics have?
ZyVersa Therapeutics has 7,935,921 shares outstanding.
What happened to ZyVersa Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of ZyVersa Therapeutics?
Currently, no hedge funds are holding shares in ZVSA
Company Description
ZyVersa Therapeutics
ZyVersa Therapeutics (ZVSA) is a clinical stage specialty biopharmaceutical company focused on developing innovative therapies to address unmet needs in the areas of renal and inflammatory diseases. The company leverages its proprietary technologies to advance a portfolio of drug candidates aimed at improving patient outcomes and quality of life. ZyVersa's core product candidates include VAR 200 for kidney diseases and IC 100 for inflammatory conditions, which are in various stages of clinical development.